Zhengye Biotechnology Reports Decline in Net Revenues to RMB 186.4 Million for 2024, Down from RMB 211.7 Million in 2023

Reuters

07-03

<a href="https://laohu8.com/S/ZYBT">Zhengye Biotechnology</a> Reports Decline in Net Revenues to RMB 186.4 Million for 2024, Down from RMB 211.7 Million in 2023

Zhengye Biotechnology Holding Ltd. has released its financial results for the fiscal year ending December 31, 2024. The company reported net revenues of RMB 186.356 million ($25.531 million), marking a decrease from RMB 211.651 million in 2023 and RMB 260.269 million in 2022. The cost of revenues for 2024 was RMB 95.061 million ($13.023 million), compared to RMB 94.143 million in the previous year and RMB 112.390 million in 2022. The company, which specializes in veterinary vaccines with a focus on livestock, has not indicated any trends or uncertainties that might materially affect its financial condition or operations in the future. Zhengye Biotechnology emphasizes that its operating results for any given period are not necessarily indicative of future outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhengye Biotechnology Holding Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-061202), on July 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2548833805"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548833805\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2548833805?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-03 18:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548833805","market":"fut","top_or_hot":-1,"title":"Zhengye Biotechnology Reports Decline in Net Revenues to RMB 186.4 Million for 2024, Down from RMB 211.7 Million in 2023","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZYBT\">Zhengye Biotechnology</a> Reports Decline in Net Revenues to RMB 186.4 Million for 2024, Down from RMB 211.7 Million in 2023\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zhengye Biotechnology Holding Ltd. has released its financial results for the fiscal year ending December 31, 2024. The company reported net revenues of RMB 186.356 million ($25.531 million), marking a decrease from RMB 211.651 million in 2023 and RMB 260.269 million in 2022. The cost of revenues for 2024 was RMB 95.061 million ($13.023 million), compared to RMB 94.143 million in the previous year and RMB 112.390 million in 2022. The company, which specializes in veterinary vaccines with a focus on livestock, has not indicated any trends or uncertainties that might materially affect its financial condition or operations in the future. Zhengye Biotechnology emphasizes that its operating results for any given period are not necessarily indicative of future outcomes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhengye Biotechnology Holding Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-061202), on July 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhengye Biotechnology Reports Decline in Net Revenues to RMB 186.4 Million for 2024, Down from RMB 211.7 Million in 2023</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhengye Biotechnology Reports Decline in Net Revenues to RMB 186.4 Million for 2024, Down from RMB 211.7 Million in 2023\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-03 18:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZYBT\">Zhengye Biotechnology</a> Reports Decline in Net Revenues to RMB 186.4 Million for 2024, Down from RMB 211.7 Million in 2023\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zhengye Biotechnology Holding Ltd. has released its financial results for the fiscal year ending December 31, 2024. The company reported net revenues of RMB 186.356 million ($25.531 million), marking a decrease from RMB 211.651 million in 2023 and RMB 260.269 million in 2022. The cost of revenues for 2024 was RMB 95.061 million ($13.023 million), compared to RMB 94.143 million in the previous year and RMB 112.390 million in 2022. The company, which specializes in veterinary vaccines with a focus on livestock, has not indicated any trends or uncertainties that might materially affect its financial condition or operations in the future. Zhengye Biotechnology emphasizes that its operating results for any given period are not necessarily indicative of future outcomes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhengye Biotechnology Holding Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-061202), on July 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZYBT","symbol_name":"正業生物","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDL3m2Qbv:1","article_id":"2548833805","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548833805","pubTimestamp":1751538739,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zhengye Biotechnology Holding Ltd. has released its financial results for the fiscal year ending December 31, 2024. The company reported net revenues of RMB 186.356 million , marking a decrease from RMB 211.651 million in 2023 and RMB 260.269 million in 2022. The cost of revenues for 2024 was RMB 95.061 million , compared to RMB 94.143 million in the previous year and RMB 112.390 million in 2022. The company, which specializes in veterinary vaccines with a focus on livestock, has not indicated any trends or uncertainties that might materially affect its financial condition or operations in the future. Zhengye Biotechnology emphasizes that its operating results for any given period are not necessarily indicative of future outcomes.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ZYBT":"正业生物"},"translate_title":"正业生物科技报告2024年净收入从2023年的2.117亿元下降至1.864亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZYBT":0.9},"content_text":"Zhengye Biotechnology Reports Decline in Net Revenues to RMB 186.4 Million for 2024, Down from RMB 211.7 Million in 2023\n    \n\n        Zhengye Biotechnology Holding Ltd. has released its financial results for the fiscal year ending December 31, 2024. The company reported net revenues of RMB 186.356 million ($25.531 million), marking a decrease from RMB 211.651 million in 2023 and RMB 260.269 million in 2022. The cost of revenues for 2024 was RMB 95.061 million ($13.023 million), compared to RMB 94.143 million in the previous year and RMB 112.390 million in 2022. The company, which specializes in veterinary vaccines with a focus on livestock, has not indicated any trends or uncertainties that might materially affect its financial condition or operations in the future. Zhengye Biotechnology emphasizes that its operating results for any given period are not necessarily indicative of future outcomes.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhengye Biotechnology Holding Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-061202), on July 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}